Ga12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4a inactivation, which causes c-Met induction

Oncotarget

Volumn 6, Issue 22, 2015, Pages 19055-19069

  Yang, Yoon Mee ^a   Lee, Chan Gyu ^a   Koo, Ja Hyun ^a   Kim, Tae Hyun ^a   Lee, Jung Min ^a   An, Jihyun ^b   Kim, Kang Mo ^b   Kim, Sang Geon ^a  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

C met; G protein; Liver cancer; Non coding RNA

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 122; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; STAT3 PROTEIN; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; MICRORNA; MIRN122 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; C MET GENE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; GALPHA12 GENE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HNF4ALPHA GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; ENZYME INDUCTION; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INDUCTION; GTP-BINDING PROTEIN ALPHA SUBUNITS, G12-G13; HEP G2 CELLS; HEPATOCYTE NUCLEAR FACTOR 4; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84938885005     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3957     Document Type: Article

References (44)

1. Burroughs A, Hochhauser D and Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004; 5:409-418.
2. Llovet JM, Burroughs A and Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362(9399):1907-1917.
3. Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245-1255.
4. Kelly P, Casey PJ and Meigs TE. Biologic functions of the G12 subfamily of heterotrimeric g proteins: growth, migration, and metastasis. Biochemistry. 2007; 46:6677-6687.
5. Ki SH, Choi MJ, Lee CH and Kim SG. Galpha12 specifically regulates COX-2 induction by sphingosine 1-phosphate. Role for JNK-dependent ubiquitination and degradation of IkappaBalpha. J Biol Chem. 2007; 282:1938-1947.
6. Kang KW, Choi SY, Cho MK, Lee CH and Kim SG. Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation. J Biol Chem. 2003; 278:17368-17378.
7. Siehler S. G12/13-dependent signaling of G-protein-coupled receptors: disease context and impact on drug discovery. Expert Opin Drug Discov. 2007; 2:1591-1604.
8. Xue YH, Zhang XF, Dong QZ, Sun J, Dai C, Zhou HJ, Ren N, Jia HL, Ye QH and Qin LX. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology. 2010; 52:2012-2022.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005; 435:834-838.
10. Hand NJ, Master ZR, Le Lay J and Friedman JR. Hepatic function is preserved in the absence of mature microRNAs. Hepatology. 2009; 49:618-626.
11. Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y and Hebrok M. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology. 2009; 136:2304-2315 e2301-2304.
12. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012; 122:2871-2883.
13. Yang YM, Lee WH, Lee CG, An J, Kim ES, Kim SH, Lee SK, Lee CH, Dhanasekaran DN, Moon A, Hwang S, Lee SJ, Park JW, Kim KM and Kim SG. Galpha gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma. Oncogene. 2014; 0.
14. Li S, Huang S and Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005; 27:1329-1339.
15. Radhika V, Hee Ha J, Jayaraman M, Tsim ST and Dhanasekaran N. Mitogenic signaling by lysophosphatidic acid (LPA) involves Galpha12. Oncogene. 2005; 24:4597-4603.
16. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H and Qu LH. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology. 2010; 52:1431-1442.
17. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12:89-103.
18. Grimminger F, Schermuly RT and Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010; 9:956-970.
19. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
20. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013; 153:1064-1079.
21. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS and Taylor JM. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004; 1:106-113.
22. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006; 3:87-98.
23. Yang YM, Seo SY, Kim TH and Kim SG. Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid. Hepatology. 2012; 56:2209-2220.
24. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M and Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122:2884-2897.
25. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L and Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67:6092-6099.
26. Coulouarn C, Factor VM, Andersen JB, Durkin ME and Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009; 28:3526-3536.
27. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117:927-939.
28. Nakamura T, Teramoto H and Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A. 1986; 83:6489-6493.
29. Montesano R, Matsumoto K, Nakamura T and Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 1991; 67:901-908.
30. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M and Nishio K. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther. 2011; 10:169-177.
31. Canadas I, Rojo F, Taus A, Arpi O, Arumi-Uria M, Pijuan L, Menendez S, Zazo S, Domine M, Salido M, Mojal S, Garcia de Herreros A, Rovira A, Albanell J and Arriola E. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res. 2014; 20:938-950.
32. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2012; 18:74-82.
33. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD and Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009; 49:1571-1582.
34. Kim VN, Han J and Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10:126-139.
35. Li ZY, Xi Y, Zhu WN, Zeng C, Zhang ZQ, Guo ZC, Hao DL, Liu G, Feng L, Chen HZ, Chen F, Lv X, Liu DP and Liang CC. Positive regulation of hepatic miR-122 expression by HNF4alpha. J Hepatol. 2011; 55:602-611.
36. Collins LR, Minden A, Karin M and Brown JH. Galpha12 stimulates c-Jun NH2-terminal kinase through the small G proteins Ras and Rac. J Biol Chem. 1996; 271:17349-17353.
37. Cho MK, Kim WD, Ki SH, Hwang JI, Choi S, Lee CH and Kim SG. Role of Galpha12 and Galpha13 as novel switches for the activity of Nrf2, a key antioxidative transcription factor. Mol Cell Biol. 2007; 27:6195-6208.
38. Jung HS, Seo YR, Yang YM, Koo JH, An J, Lee SJ, Kim KM and Kim SG. Galpha12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation. Cell Signal. 2014; 26:1456-1465.
39. Yang YM, Lee S, Nam CW, Ha JH, Jayaraman M, Dhanasekaran DN, Lee CH, Kwak MK and Kim SG. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis. 2010; 31:1230-1237.
40. Almendro V, Garcia-Recio S and Gascon P. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets. 2010; 11:1169-1180.
41. Fischer OM, Giordano S, Comoglio PM and Ullrich A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem. 2004; 279:28970-28978.
42. Lee SJ, Yang JW, Cho IJ, Kim WD, Cho MK, Lee CH and Kim SG. The gep oncogenes, Galpha(12) and Galpha(13), upregulate the transforming growth factor-beta1 gene. Oncogene. 2009; 28:1230-1240.
43. Kumar RN, Shore SK and Dhanasekaran N. Neoplastic transformation by the gep oncogene, Galpha12, involves signaling by STAT3. Oncogene. 2006; 25:899-906.
44. Freedman VH and Shin SI. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 1974; 3:355-359.